Aging
Navigate
Research Paper|Volume 15, Issue 14|pp 6798—6821

Molecular subtypes based on DNA sensors predict prognosis and tumor immunophenotype in hepatocellular carcinoma

Hong-Sheng Lin1,2, Wen-Peng Pang1, Hao Yuan3, Yin-Zhi Kong2, Fu-Li Long4, Rong-Zhen Zhang4, Li Yang2, Qiao-Ling Fang2, Ai-Ping Pan2, Xiao-Hui Fan1, Ming-Fen Li2
  • 1Department of Microbiology, School of Basic Medical Sciences, Guangxi Medical University, Nanning 530021, China
  • 2Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China
  • 3Department of Immunology, School of Basic Medical Sciences, Guangxi Medical University, Nanning 530021, China
  • 4Department of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China
* Equal contribution and co-first authors
Received: December 27, 2022Accepted: June 19, 2023Published: July 14, 2023

Copyright: © 2023 Lin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

DNA sensors play crucial roles in inflammation and have been indicated to be involved in antitumor or tumorigenesis, while it is still unclear whether DNA sensors have potential roles in the prognosis and immunotherapy of hepatocellular carcinoma (HCC). Herein, The Cancer Genome Atlas and Gene Expression Omnibus databases were used to analyze RNA sequencing data and clinical information. A total of 14 DNA sensors were collected and performed consensus clustering to determine their molecular mechanisms in HCC. Two distinct molecular subtypes (Clusters C1 and C2) were identified and were associated with different overall survival (OS). Immune subtype analysis revealed that C1 was mainly characterized by inflammation, while C2 was characterized by lymphocyte depletion. Immune scoring and immunomodulatory function analysis confirmed the different immune microenvironment of C1 and C2. Notably, significant differences in “Hot Tumor” Immunophenotype were observed between the two subtypes. Moreover, the prognostic model based on DNA sensors is capable of effectively predicting the OS of HCC patients. Besides, the chemotherapeutic drug analysis showed the different sensitivity of two subtypes. Taken together, our study shows that the proposed DNA sensors were a reliable signature to predict the prognosis and immunotherapy response with potential application in the clinical decision and treatment of HCC.